Ardelyx signs termination agreement with AstraZeneca, regains privileges to portfolio of NHE3 inhibitors Ardelyx, Inc prednisone20.net . , a clinical-stage biopharmaceutical business focused on cardio-renal, metabolic and gastrointestinal diseases, today announced that it provides entered right into a termination contract with AstraZeneca , such that all the privileges to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product applicant, tenapanor, are returned to Ardelyx. Ardelyx has decided to pay AstraZeneca $15 million upfront along with other future contingent obligations.
prednisone over the counter
In 2006, the Company sold all assets related to the Intraject* needle-free injector technology to Zogenix in exchange for milestone and royalty obligations.S. Drug and Food Administration approved SUMAVEL DosePro for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headaches. SUMAVEL DosePro delivers subcutaneous sumatriptan, a treatment that provides migraine alleviation, in a first-of-its-kind needle-free delivery system. Migraine is definitely a chronic and common neurovascular disorder characterized by episodic episodes. According to a 2004 report from the National Headaches Foundation, approximately 30 million people in the U.S. Suffer from migraines. Both men and women experience migraine, although women are three times more likely to suffer from it.